When was NeuroBio founded?

NeuroBio was founded in 2013 and raised its 1st funding round within a year of its incorporation.

Where is NeuroBio located?

NeuroBio is headquartered in Oxford, United Kingdom. It is registered at Building F5, Culham Science Centre, Abingdon, Oxfordshire, England, OX14 3DB.

Which legal entities is NeuroBio associated with?

NeuroBio is associated with Neuro-bio Ltd.

How many employees does NeuroBio have?

As of Sep 30, 2026, the latest employee count at NeuroBio is 16.

Is NeuroBio a funded company?

NeuroBio is a funded company, having raised a total of $14.1M across 12 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 27, 2013.

How much is NeuroBio worth?

The latest valuation of NeuroBio is £***** as of Aug 16, 2023.

When was the latest funding round of NeuroBio?

NeuroBio's latest funding was a $***** Series A round on Aug 16, 2023, with participation from 0 investor.

Where does NeuroBio rank among its competitors?

NeuroBio ranks 9th amongst 43 active competitors, of which 14 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Seek Labs, which secured $2M in Feb, 2026.

Who are the top competitors of NeuroBio?

NeuroBio's top competitors include Cytonics, Circular Genomics and Treos Bio. Among them, Seek Labs secured the most recent funding round in February, 2026.

NeuroBio - 2026 Company Profile, Funding, Competitors & Financials

NeuroBio is a series A company based in Oxford (United Kingdom), founded in 2013. It operates as an UK-based, preclinical stage biopharma startup developing therapeutics for Alzheimer's disease.. NeuroBio has raised $14.1M in funding, with a current valuation of £*****. The company has 43 active competitors, including 14 funded and 7 that have exited. Its top competitors include companies like Cytonics, Circular Genomics and Treos Bio.

Company Details

NeuroBio is a UK-based, preclinical stage biopharma startup developing therapeutics for Alzheimer's disease. Acetyl Choline Esterase (AChE) is the enzyme responsible for breaking down acetylcholine, which leads to disease progression in Alzheimer's. Neuro-Bio has identified a peptide derived from AChE and has a claim that this fragment is the main pathological driver in Alzheimer's disease, by acting in parts of the brain impacted in early disease stage. The company is developing inhibitors of the peptide to create a disease-modifying therapy. The company seeks investments to begin preclinical studies.

Website: neuro-bio.com
Social
Email ID: *****@neuro-bio.com
Registered Address: Building F5, Culham Science Centre, Abingdon, Oxfordshire, England, OX14 3DB

Key Metrics

Founded Year

2013

Location

Oxford, United Kingdom

Stage

Series A

Total Funding

$14.1M in 12 rounds

Latest Funding Round

Series A, Aug 16, 2023, $*****

Post Money Valuation

£***** as on Aug 16, 2023

Investors

Michael Spencer & 60 more

Ranked

9^th among 43 active competitors

Employee Count

16 as on Sep 30, 2026

Similar Companies

Cytonics & 52 more

View NeuroBio's full profile

NeuroBio is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Neuro-bio Ltd CIN: 8580518 , United Kingdom, Active	Jun 20, 2013	-	10 (As on Dec 31, 2021)

NeuroBio has raised a total funding of $14.1M over 12 rounds. Its first funding round was on Nov 27, 2013. NeuroBio has 15 institutional investors and 46 angel investors.

Here is the list of recent funding rounds of NeuroBio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 16, 2023	7402490	Series A	1544683	3218681	4808885	9867983
Nov 12, 2020	3460989	Series A	3671779	9260313	3444755	9218121
Oct 16, 2019	8611010	Series A	6688103	6893490	1167187	8241898

Access funding benchmarks and valuations. Sign up today!

View details of NeuroBio's funding rounds and investors

NeuroBio's employee count trend

NeuroBio has 16 employees as of Sep 26. Here is NeuroBio's employee count trend over the years:

Uncover NeuroBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NeuroBio include Cytonics, Circular Genomics and Treos Bio. Here is the list of Top 10 competitors of NeuroBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cytonics 2006, Jupiter (United States), Seed	Developer of biologic therapies targeting molecular drivers of cartilage degradation	$3.33M	NIH SBIR/STTR, HHS & 1 others	55/100
2nd	Circular Genomics 2021, Albuquerque (United States), Series A	Provider of RNA-based diagnostics and therapeutics to treat depression	$29M	Mountain Group Partners, Cottonwood Technology Fund ... & 3 others	55/100
3rd	Treos Bio 2013, London (United Kingdom), Series B	Developer of cancer vaccines and companion diagnostics	$22M	Luminous Ventures, Hopkins Capital & 43 others	53/100
4th	PierianDx 2014, Saint Louis (United States), Acquired	Provider of genetic tests for individualized diagnosis of multiple diseases	$69.4M	ATW Partners, Orbimed & 12 others	53/100
5th	Ulisse BioMed 2015, Udine (Italy), Series B	Manufacturer of biological drug monitoring and molecular diagnostics	$17.6M	Europa, Global Corporate Finance	53/100
6th	Telix Pharma 2015, Melbourne (Australia), Public	Developer of theranostic radiopharmaceuticals for imaging and treating cancer	-	China Grand Pharmaceutical and Healthcare	52/100
7th	Ignyta 2011, San Diego (United States), Acquired	Personalized medicine for cancer and autoimmune diseases	$96.9M	Colt Ventures, City Hill Ventures & 7 others	51/100
8th	Seek Labs 2017, Salt Lake City (United States), Series B	Developer of a technology for the treatment and diagnostics of infectious diseases.	$13.6M	United States Department of Agriculture	49/100
9th	NeuroBio 2013, Oxford (United Kingdom), Series A	UK-based, preclinical stage biopharma startup developing therapeutics for Alzheimer's disease.	$14.1M	Kairos Ventures, Harold Mitchell Super & 59 others	40/100
10th	Xiantong Pharmaceutical 2004, Beijing (China), Series E	Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases and cardiovascular diseases.	$99.5M	Goldstone Investment , SDIC & 13 others	42/100